Stock Research: Aspen Pharmacare

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Aspen Pharmacare

JNB:APN ZAE000066692
19
  • Value
    100
  • Growth
    8
  • Safety
    Safety
    38
  • Combined
    45
  • Sentiment
    6
  • 360° View
    360° View
    19
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Aspen Pharmacare Holdings Limited is a global pharmaceutical company. It focuses on marketing and manufacturing a range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets, including the key brands Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine. Aspen Pharmacare Holdings Limited operates in South Africa and other global markets. In the last fiscal year, the company had a market cap of $2,813 million, profits of $1,070 million, revenue of $2,458 million, and 8,867 employees.

more
Index
JSE All Shares
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
100 91 99 89
Growth
8 27 45 77
Safety
Safety
38 39 41 7
Sentiment
6 71 90 55
360° View
360° View
19 65 88 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
11 73 79 46
Opinions Change
50 23 72 50
Pro Holdings
n/a 80 73 26
Market Pulse
10 70 42 81
Sentiment
6 71 90 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
100 91 99 89
Growth
8 27 45 77
Safety Safety
38 39 41 7
Combined
45 53 75 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
78 77 82 78
Price vs. Earnings (P/E)
94 97 93 81
Price vs. Book (P/B)
94 89 91 91
Dividend Yield
72 82 81 76
Value
100 91 99 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
4 26 54 78
Profit Growth
48 39 48 76
Capital Growth
22 45 21 21
Stock Returns
8 39 79 79
Growth
8 27 45 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
35 24 34 36
Refinancing
74 88 90 1
Liquidity
33 24 28 24
Safety Safety
38 39 41 7

Similar Stocks

Discover high‑ranked alternatives to Aspen Pharmacare and broaden your portfolio horizons.

Omnia

JNB:OMN
Country: South Africa
Industry: Diversified Chemicals
Size: Medium
Full Stock Analysis

Astral Foods

JNB:ARL
Country: South Africa
Industry: Packaged Foods & Meats
Size: Medium
Full Stock Analysis

Exxaro

JNB:EXX
Country: South Africa
Industry: Coal & Consumable Fuels
Size: Medium
Full Stock Analysis

Ninety One

JNB:NY1
Country: South Africa
Industry: Asset Management & Custody
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The only strength is good value. All other factors (growth, safety, and sentiment) are below average. This stock is highly sensitive to a crisis and is not advisable. Avoid unless you have solid, independent reasons to believe a significant turnaround is imminent.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: